Understanding The NAChR Alpha3beta2 Receptor: A Potential Drug Target for Neurological Disorders

Target Name: Nicotinic alpha3beta2 receptor

NCBI ID: P32822

Nicotinic alpha3beta2 receptor

Other Name(s): nAChR alpha3beta2 receptor

Understanding The NAChR Alpha3beta2 Receptor: A Potential Drug Target for Neurological Disorders

The Nicotinic alpha3beta2 receptor (nAChR alpha3beta2 receptor) is a G protein-coupled receptor (GPCR) that plays a crucial role in various physiological processes in the body. It is a member of the nicotinic receptor family, which includes GPCRs that are involved in the regulation of pain, inflammation, and neurotransmitter release. The nAChR alpha3beta2 receptor is expressed in various tissues and is involved in the regulation of pain perception, neurogenic pain, and neuroprotection.

The nAChR alpha3beta2 receptor is a transmembrane receptor that is characterized by its extracellular domain, which is composed of a single transmembrane alpha-helices and a single carboxylic acid residue. The alpha-helices are involved in the formation of the receptor's extracellular domain, which is involved in its stability and function. The carboxylic acid residue is involved in the regulation of the receptor's activity and interacts with other molecules in the cell.

The nAChR alpha3beta2 receptor is involved in the regulation of pain perception and neurogenic pain. Pain perception is the body's response to tissue damage, which can be caused by various stimuli, such as pressure, temperature, or chemical irritants. The nAChR alpha3beta2 receptor is involved in the regulation of pain perception by modulating the activity of other GPCRs, such as the n pain receptor (NPRG1) and the delta-opioid receptor (DOR).

The nAChR alpha3beta2 receptor is also involved in the regulation of neurogenic pain, which is pain that is generated by injured or diseased tissues. Neurogenic pain is caused by the release of pro-inflammatory cytokines, which can cause pain perception and inflammation in the damaged tissue. The nAChR alpha3beta2 receptor is involved in the regulation of neurogenic pain by modulating the activity of other GPCRs, such as the pain-perceptionrelated GPCR (PVBP) and the neurogenic pain receptor (PGPR).

In addition to its role in pain perception and neurogenic pain, the nAChR alpha3beta2 receptor is also involved in the regulation of neuroprotection. Neuroprotection is the process by which the brain and other organs protect themselves from damage and inflammation. The nAChR alpha3beta2 receptor is involved in neuroprotection by modulating the activity of other GPCRs, such as the brain-derived neurotrophic factor (BDNF) and the neuroprotective factor (NPF).

The nAChR alpha3beta2 receptor is a potential drug target and biomarker for various neurological and psychiatric disorders. For example, the nAChR alpha3beta2 receptor is involved in the regulation of pain perception and neurogenic pain, which are associated with a number of disorders, such as chronic pain, neurodegenerative diseases, and psychiatric disorders. The nAChR alpha3beta2 receptor is also involved in the regulation of neuroprotection, which is associated with a number of disorders, such as neuroinflammation and psychiatric disorders.

The nAChR alpha3beta2 receptor is a GPCR that plays a crucial role in various physiological processes in the body. It is involved in the regulation of pain perception, neurogenic pain, and neuroprotection. As a result, the nAChR alpha3beta2 receptor is a potential drug target and biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of the nAChR alpha3beta2 receptor in the regulation of pain perception and neurogenic pain, as well as its potential as a drug target and biomarker.

Protein Name: Nicotinic Alpha3beta2 Receptor

The "Nicotinic alpha3beta2 receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nicotinic alpha3beta2 receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets